Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int Immunopharmacol ; 8(3): 401-13, 2008 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18279794

RESUMO

Optimization of the use of monoclonal antibodies (MAbs) as diagnostic tools and therapeutic agents in the treatment of cancer is aided by quantitative characterization of the transport and tissue disposition of these agents in whole animals. This characterization may be effectively achieved by the application of physiologically based pharmacokinetic (PBPK) models. The purpose of this study was to develop a PBPK model to characterize the biodistribution of the pancarcinoma MAb CC49 IgG in normal and neoplastic tissues of nude mice, and to further apply the model to predict the disposition of multivalent single chain Fv (scFv) constructs in mice. Since MAbs are macromolecules, their transport is membrane-limited and a two-pore formalism is employed to describe their extravasation. The influence of binding of IgG to the protective neonatal Fc receptor (FcRn) on its disposition is also accounted for in the model. The model successfully described (131)I-CC49 IgG concentrations in blood, tumor and various organs/tissues in mice. Sensitivity analysis revealed the rate of transcapillary transport to be a critical determinant of antibody penetration and localization in the tumor. The applicability of the model was tested by predicting the disposition of di- and tetravalent scFv constructs of CC49 in mice. The model gave reasonably good predictions of the disposition of the scFv constructs. Since the model employs physiological parameters, it can be used to scale-up mouse biodistribution data to predict antibody distribution in humans. Therefore, the clinical utility of the model was tested with data for (131)I-CC49 obtained in patients, by scaling up murine parameter values according to known empirical relationships. The model gave satisfactory predictions of CC49 disposition and tumor uptake in man.


Assuntos
Anticorpos Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Fragmentos de Imunoglobulinas/metabolismo , Neoplasias Experimentais/metabolismo , Radioimunoterapia , Animais , Feminino , Humanos , Radioisótopos do Iodo/uso terapêutico , Camundongos , Modelos Biológicos , Distribuição Tecidual
2.
J Pharm Sci ; 91(7): 1733-41, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12115836

RESUMO

The physico-chemical solution properties of deferoxamine were modified by acylating the terminal amino group with short-chain aliphatic, succinic, and methylsulphonic moieties. The analog iron(III)-binding constants and stabilities under physiological conditions were determined to confirm that the iron binding ability of the parent molecule was retained following modification. The proton dissociation constants of the lipophilic deferoxamine analogs were determined by potentiometric titration and nonlinear least-squares analysis. However, because the iron(III) binding complex is fully formed below pH 2, the metal-ligand equilibria could not be studied using potentiometric methods. The iron binding constants of the deferoxamine analogs were determined by spectrophotometrically following the proton-dependent exchange of iron with EDTA in the pH range of 4.0 to 6.5 and solving mass balance equations. The proton-dissociation constants and the iron binding constants of the lipophilic deferoxamine analogs were comparable to those of deferoxamine. However, at physiological conditions, the iron-binding complex of the most lipophilic butylamide derivative was slightly less stable and the succinamide derivative complex was slightly more stable. Like deferoxamine, the hydroxamate groups of the analogs were unhindered and free to form a 1:1 coordination complex with iron(III). Consequently, changes in aqueous solvation, conformation, and steric interference, imparted by the modifications at the terminal amino group of deferoxamine, may have affected the stabilities of the iron(III) complex and the efficiency of iron binding.


Assuntos
Amidas/química , Desferroxamina/química , Desferroxamina/análogos & derivados , Estabilidade de Medicamentos , Íons/química , Soluções Farmacêuticas/química
3.
AAPS PharmSciTech ; 5(4): e53, 2004 Sep 13.
Artigo em Inglês | MEDLINE | ID: mdl-15760050

RESUMO

The purpose of this study was to investigate the effect of particle size, storage temperature, and duration of storage on the physical stability and morphology of polylactic-co-glycolic acid (PLGA) nanospheres and microspheres. PLGA nanospheres and microspheres containing the fluorescent dye, Bodipy, were prepared in varying sizes by controlling the method and degree of agitation during the emulsification phase of preparation. Mean diameters of the particles were measured by dynamic light scattering. To evaluate the effect of storage temperature and duration of storage on the extent of aggregation, nanospheres and microspheres were stored at 4 degrees C, 25 degrees C, 37 degrees C, and 50 degrees C for 6 days and then monitored using both confocal and scanning electron microscopy. The mean +/- SD diameters of PLGA particles containing Bodipy were: 266.9 +/- 2.8, 351.6 +/- 1.8, 988.8 +/- 14.1, and 1865.9 +/- 67.0 nm. The extent of aggregation of the particulate delivery system decreased as the mean diameter increased, and increased as the storage temperature increased. The maximum extent of aggregation was observed with the smallest (266 nm) nanospheres. Microspheres did not aggregate. The aggregation of nanospheres was significantly reduced by introducing an additional evaporation step during preparation, suggesting that migration of residual dichloromethane from within the nanospheres may have dissolved the PLGA on the surface. The extent of aggregation of nanospheres increased as the temperature was increased from 4 degrees C to 50 degrees C, and decreased as particle size increased. To avoid aggregation, PLGA nanospheres should be stored at 4 degrees C.


Assuntos
Compostos de Boro/química , Ácido Láctico/química , Nanotubos/química , Ácido Poliglicólico/química , Polímeros/química , Temperatura , Estabilidade de Medicamentos , Armazenamento de Medicamentos/métodos , Microesferas , Nanotubos/ultraestrutura , Tamanho da Partícula , Copolímero de Ácido Poliláctico e Ácido Poliglicólico
4.
J Diet Suppl ; 10(3): 241-51, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23957855

RESUMO

Creatine ethyl ester hydrochloride (CEE) was synthesized as a prodrug of creatine (CRT) to improve aqueous solubility, gastrointestinal permeability, and ultimately the pharmacodynamics of CRT. We used high-performance liquid chromatography (HPLC) and proton nuclear magnetic resonance (NMR) to characterize the pH-dependent stability of CEE in aqueous solution and compared the permeability of CEE to CRT and creatinine (CRN) across Caco-2 human epithelial cell monolayers and transdermal permeability across porcine skin. CEE was most stable in a strongly acidic condition (half-life = 570 hours at pH 1.0) where it undergoes ester hydrolysis to CRT and ethanol. At pH ≥ 1.0, CEE cyclizes to CRN with the logarithm of the first order rate constant increasing linearly with pH. Above pH 8.0 (half-life = 23 sec) the rate of degradation was too rapid to be determined. The rate of degradation of CEE in cell culture media and simulated intestinal fluid (SIF) was a function of pH and correlated well with the stability in aqueous buffered solutions. The permeability of CEE across Caco-2 monolayers and porcine skin was significantly greater than that of CRT or CRN. The stability of CEE in acidic media together with its improved permeability suggests that CEE has potential for improved oral absorption compared to CRT.


Assuntos
Creatina/análogos & derivados , Creatina/metabolismo , Ácido Gástrico , Mucosa Intestinal/metabolismo , Pró-Fármacos/metabolismo , Pele/metabolismo , Administração Oral , Animais , Células CACO-2 , Química Farmacêutica , Creatina/administração & dosagem , Creatinina/metabolismo , Estabilidade de Medicamentos , Humanos , Concentração de Íons de Hidrogênio , Pró-Fármacos/administração & dosagem , Suínos
5.
Int J Pharm ; 409(1-2): 111-20, 2011 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-21356285

RESUMO

We have previously demonstrated that the cellular association, cytotoxicity, and in vivo anti-tumor efficacy of paclitaxel are significantly greater when delivered in PLGA microparticles compared to nanoparticles. The purpose of this research is to test the hypothesis that mucoadhesive chitosan promotes adhesion of PLGA particles to mucus on the tumor epithelium, resulting in enhanced cellular association and cytotoxicity of paclitaxel. PLGA particles containing paclitaxel or Bodipy(®) were prepared and chitosan was either adsorbed or chemically conjugated to the particle surface. The cellular association and cytotoxicity of paclitaxel in 4T1 cells was determined. A 4-10 fold increase in cellular association of paclitaxel was observed when chitosan was adsorbed or conjugated to the PLGA particles. Chitosan-conjugated PLGA microparticles were most cytotoxic with an IC(50) value of 0.77 µM. Confocal microscopy demonstrated that chitosan-PLGA microparticles adhered to the surface of 4T1 cells. Pretreatment of either 4T1 cells or chitosan-PLGA particles with mucin resulted in significant increase in cellular association of paclitaxel. A linear correlation was established between theoretical amount of chitosan used and experimentally determined amount of chitosan adsorbed or conjugated to PLGA nanoparticles. In conclusion, cellular association and cytotoxicity of paclitaxel was significantly enhanced when delivered in chitosan-PLGA particles.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Quitosana/química , Ácido Láctico/química , Paclitaxel/farmacologia , Ácido Poliglicólico/química , Adesividade , Animais , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/farmacocinética , Compostos de Boro/administração & dosagem , Compostos de Boro/química , Linhagem Celular Tumoral , Portadores de Fármacos/química , Feminino , Concentração Inibidora 50 , Neoplasias Mamárias Animais/tratamento farmacológico , Neoplasias Mamárias Animais/patologia , Camundongos , Microscopia Confocal , Microesferas , Paclitaxel/administração & dosagem , Paclitaxel/farmacocinética , Copolímero de Ácido Poliláctico e Ácido Poliglicólico
6.
Int J Pharm ; 383(1-2): 37-44, 2010 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-19747969

RESUMO

This research compares the anti-tumor efficacy of paclitaxel delivered intratumorally in PLGA nanoparticles, microparticles, or the commercial Paclitaxel Injection((R)). The hypothesis of the research is that larger PLGA microparticles adhere to mucus on the cell surface, release paclitaxel locally, and enhance cellular association of paclitaxel. PLGA-paclitaxel particles of mean diameters 315 nm, 1 microm, and 10 microm were prepared and their drug content, in vitro release, and cellular association of paclitaxel into 4T1 cells quantified. These particles were injected intratumorally into tumor xenografts, and the tumor volumes monitored over 13 days. Mean tumor volumes of the groups that received placebo and the 315 nm nanoparticles increased 2 and 1.5 times, respectively. Tumor growth was arrested in groups that received 1 microm and 10 microm microparticles. Additional cell culture studies were performed to test the hypothesis. The size-dependent increase in cellular concentration of paclitaxel was independent of duration of incubation of PLGA particles with 4T1 cells, and was enhanced 1.5 times by coating the particles or 4T1 cells with mucin. These particles were not internalized by clathrin-mediated endocytosis or macropinocytosis. In conclusion, PLGA microparticles sustained drug release, increased cellular concentration, and enhanced anti-tumor efficacy of paclitaxel compared to nanoparticles and Paclitaxel Injection.


Assuntos
Antineoplásicos Fitogênicos/administração & dosagem , Sistemas de Liberação de Medicamentos/métodos , Microesferas , Nanopartículas/administração & dosagem , Paclitaxel/administração & dosagem , Animais , Antineoplásicos Fitogênicos/metabolismo , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Feminino , Camundongos , Camundongos Endogâmicos BALB C , Paclitaxel/metabolismo , Células Tumorais Cultivadas
7.
J Diet Suppl ; 7(3): 240-52, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22432515

RESUMO

Creatine is widely used as a dietary supplement for body builders to enhance athletic performance. As the monohydrate, its low solubility in water and high dose lead to water retention and gastrointestinal discomfort. Hence, alternative creatine derivatives with enhanced water solubility and potential therapeutic advantages have been synthesized. As a zwitterionic compound, creatine can form salts at the N-methyl guanidinium or carboxylic acid functional groups. In this study, we determined the aqueous solubilities and partition coefficients of six N-methyl guanidinium salts of creatine compared to those of creatine monohydrate; two of these were new salts, namely, creatine mesylate and creatine hydrogen maleate. The aqueous solubilities of the salts were significantly more than that of creatine monohydrate with the hydrochloride and mesylate being 38 and 30 times more soluble, respectively. The partition coefficients of the creatine salts were very low indicating their relatively high polarity. Permeabilities of creatine pyruvate, citrate, and hydrochloride in Caco-2 monolayers were compared to that of creatine monohydrate. Aside from the creatine citrate salt form that had reduced permeability, there were no significant differences in permeability characteristics in Caco-2 monolayers. Typical of an amphoteric compound, creatine is least soluble in the pH region near the isoelectric point.


Assuntos
Creatina/química , Suplementos Nutricionais , Desempenho Atlético , Células CACO-2 , Guanidina , Humanos , Concentração de Íons de Hidrogênio , Permeabilidade , Sais/química , Solubilidade
8.
Pharm Res ; 22(5): 766-75, 2005 May.
Artigo em Inglês | MEDLINE | ID: mdl-15906172

RESUMO

PURPOSE: To compare the effect of size of delivery systems on the cell-association and in vitro cytotoxicity of paclitaxel. METHODS: Four sizes of PLGA-paclitaxel particles were prepared to study the effect of particle size on the cell-association of paclitaxel in 4T1 monolayer in the presence, and absence, of BCRP inhibitor, endocytic inhibitor, and P-glycoprotein (P-gp) inhibitor. Paclitaxel cell-association studies were repeated in Caco-2, Cor-L23/R, and bovine brain microvessel endothelial cells (BBMECs), as well as the association of etoposide in 4T1 cells. Cytotoxicity of paclitaxel to 4T1 cells delivered in nanospheres was compared to microspheres. RESULTS: The concentration of paclitaxel and etoposide associated with 4T1 cells was 4.8 and 29 times greater, respectively, as the size increased from 310 to 2077 nm. Paclitaxel association consistently increased in Caco-2 and Cor-L23/R as the size of the delivery system increased. The endocytic inhibitor, 2-deoxyglucose, significantly decreased the cellular paclitaxel association when delivered by nanospheres but not microspheres. Consistent with the cell-association results, paclitaxel was thrice more cytotoxic to 4T1 cells when delivered in microspheres. CONCLUSIONS: Cell-association of paclitaxel increased in 4T1, Caco-2, and Cor-L23/R as particle size increased. Paclitaxel delivered from 1-mum microspheres was thrice more cytotoxic to 4T1 cells compared to the drug delivered from nanospheres or solution.


Assuntos
Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Microesferas , Nanotubos/química , Paclitaxel/farmacocinética , Tamanho da Partícula , Subfamília B de Transportador de Cassetes de Ligação de ATP/antagonistas & inibidores , Subfamília B de Transportador de Cassetes de Ligação de ATP/biossíntese , Animais , Compostos de Boro/química , Compostos de Boro/farmacologia , Encéfalo/irrigação sanguínea , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Bovinos , Química Farmacêutica/métodos , Ciclosporina/farmacologia , Desoxiglucose/farmacologia , Ensaios de Seleção de Medicamentos Antitumorais/métodos , Endocitose/efeitos dos fármacos , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/patologia , Etoposídeo/análise , Etoposídeo/química , Etoposídeo/farmacologia , Ácido Láctico/química , Ácido Láctico/farmacologia , Paclitaxel/análise , Paclitaxel/química , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacologia , Copolímero de Ácido Poliláctico e Ácido Poliglicólico , Polímeros/química , Polímeros/farmacologia
9.
J Biomater Sci Polym Ed ; 15(10): 1317-26, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15559852

RESUMO

We previously demonstrated that cylindrical, biodegradable reservoirs fabricated with polylactide-polyethylene glycol (PLLA:PEG) films maintain constant permeability and enable zero-order drug delivery for up to 6 weeks in vitro. This research proposes that PEG not only enhances permeability but also extends of life of the device by allowing the escape of soluble degraded monomers thereby minimizing autocatalysis of PLLA. To test this hypothesis, cylindrical PLLA films with varying PEG concentrations (0-30%, w/w) and film-thickness (0.05-0.18 mm) were fabricated, and their degradation rate and thermal properties monitored for 23 weeks in vitro. The decrease in PLLA molecular weight for all films followed bi-exponential kinetics that fit the equation: y(t) = M(e(-K1t) + e(-K2t)), as was determined by a Pearson's coefficient > 0.95 for all films. The constant M was empirically determined to be equal to have the initial molecular weight of the degrading polymer. The value of K1 was 5-60 orders of magnitude greater than K2 and was attributed to the autocatalytic degradation based on its dependence on PEG concentration, film thickness, and correlation with the enthalpy change associated with the glass transition (deltaCp). K2 was attributed to simple hydrolytic cleavage of PLLA. The decrease in the value of K1 with PEG concentration and thickness, and the correlation of K1 with deltaCp, confirmed that the PLLA degradation can be controlled by incorporating PEG, as well as by modifying thickness.


Assuntos
Materiais Biocompatíveis , Sistemas de Liberação de Medicamentos , Lactatos/química , Poliésteres/química , Polietilenoglicóis/química , Catálise , Relação Dose-Resposta a Droga , Vidro , Temperatura Alta , Concentração de Íons de Hidrogênio , Cinética , Ácido Láctico/química , Polímeros/química , Temperatura , Termodinâmica , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA